Daily FNArena News - Australia

AMP has lost a third of its value over the course of the Royal Commission. Is it now a bargain, or is the worst yet to come?

Stockbrokers are still not keen on buying Sigma Healthcare shares, though a capital return might change their view.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Aurizon has re-confirmed FY18 guidance but signalled a deteriorating outlook for FY19. Broker attitudes vary widely, given the regulatory uncertainties hanging over the stock.

Many brokers consider Link Administration has become a compelling Buy after recently de-rating on the back of reform proposals and the loss of a major account.

Despite some positives in the FY18 results, brokers question the lack of organic growth in the Metcash food business and also whether a buyback is the appropriate use of the company’s cash.

Commonwealth Bank intends to de-merge its wealth management businesses and brokers, while mildly positive about the development, emphasise that heightened risks continue.

Rising supply and weakening house price growth look set to peg back the housing industry but analysts are not perturbed and envisage any slowdown will be modest.

Northern Star Resources has achieved production rates targeted for the next two years but new milling capacity could provide even more upside.

Ramsay Health Care has downgraded FY18 growth estimates amid weak conditions in both Australian and UK private hospital markets.